Clinical Significance of FOXP3 Expression in BRCA1/2-Mutant Breast Cancer
10.3971/j.issn.1000-8578.2024.24.0134
- VernacularTitle:FOXP3在BRCA1/2突变乳腺癌中的表达及临床意义
- Author:
Linxi CHEN
1
;
Li HU
;
Jiuan CHEN
;
Lu YAO
;
Juan ZHANG
;
Ye XU
;
Yuntao XIE
Author Information
1. 100142 北京,北京大学肿瘤医院家族遗传性肿瘤中心实验室
- Keywords:
BRCA1/2 mutation;
Breast cancer;
FOXP3;
Homologous recombination deficiency
- From:
Cancer Research on Prevention and Treatment
2024;51(7):561-566
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the potential significance of FOXP3 expression in BRCA1/2-mutant breast cancer.Methods A total of 48 BRCA mutation carriers(16 with BRCA1 and 32 with BRCA2)and 78 age-matched non-carriers were included in this study.Immunohistochemistry was used to detect the expression of FOXP3 in breast cancer tissues.The FOXP3 RNA expression in 39 BRCA1,36 BRCA2,and 948 non-carrier breast cancer patients from TCGA-BRCA and the correlation with homologous recombin-ation deficiency scores were evaluated to validate the immunohistochemistry results.Results The FOXP3 positive rate was 43.8%(7/16)in BRCA1 mutation carriers,59.4%(19/32)in BRCA2 mutation carriers,and 9.0%(7/78)in non-carriers.The FOXP3 positive rates in patients with BRCA1/2 mutant breast cancer were significantly higher than those in non-carriers(P=0.002;P<0.001).TCGA-BRCA results showed that the FOXP3 RNA level in BRCA1/2 mutant breast cancer was significantly higher than that in non-carriers(P=0.02,P=0.004).The FOXP3 RNA level was positively correlated with the homologous recombination deficiency score(Spearman R=0.30,P<2.2e-16).Conclusion Patients with BRCA1/2 mutant breast cancers have higher FOXP3expression than non-carriers,and may be more sensitive to immunotherapy.
